Introduction

In regulatory strategy for medical devices, one approach continues to be widely used—especially when time and budget are limited:

“Let’s rely on literature for clinical evidence.”

At first glance, this seems practical. Published studies are peer-reviewed, readily available, and often provide years of clinical insights. For many manufacturers, literature appears to be a reliable way to demonstrate safety and performance without conducting new clinical investigations.

However, under EU MDR, literature-only clinical evidence often fails.

Not because literature is unreliable—but because it is frequently misapplied and insufficient on its own.

The Role of Literature in Clinical Evaluation

Literature is an important component of clinical evaluation. When used correctly, it can:

• Support the state of the art
• Provide background on clinical practices
• Contribute to safety and performance data
• Strengthen overall clinical arguments

Guidance such as MEDDEV 2.7/1 Rev 4 allows the use of literature as part of a broader evidence strategy.

But here’s the key point:

Literature is meant to support clinical evidence—not replace it.

Why Literature-Only Approaches Fail

1. Poor Device Comparability

One of the most common issues is assuming that literature automatically applies to your device.

In reality, regulators expect clear demonstration that the device described in the literature is comparable in terms of:

• Design
• Materials
• Intended use
• Performance characteristics

Even small differences can significantly impact safety and effectiveness.

Without strong comparability, literature becomes irrelevant to your device.

2. Weak Clinical Relevance

Many literature-based submissions include studies that are not directly applicable.

Common issues include:

• Different patient populations
• Different indications
• Different clinical environments

While such studies may be scientifically valid, they do not necessarily support your specific claims.

Relevance is more important than volume.

3. Insufficient Data Depth

Literature often provides high-level information but lacks detailed, device-specific data.

Limitations may include:

• Limited adverse event reporting
• Short follow-up periods
• Aggregated outcomes that do not isolate device performance

This creates gaps that cannot be filled by general data.

4. Overreliance on Outdated Studies

Under EU MDR, clinical evidence must reflect the current state of the art.

Outdated literature may:

• Reflect older technologies
• Miss recent safety concerns
• Not align with current clinical practices

This weakens the overall evaluation

5. Lack of Critical Appraisal

Including literature is not enough.

Each study must be:

• Critically assessed for quality
• Evaluated for bias
• Reviewed for relevance

A common mistake is summarizing studies without evaluating their strengths and limitations.

6. Weak Linkage Between Evidence and Claims

This is the biggest reason literature-only approaches fail.

Manufacturers often present multiple studies but fail to clearly explain:

• How the data supports specific safety and performance claims
• How differences are addressed
• Why the evidence is sufficient

Evidence without interpretation is not a justification.

7. Ignoring Data Gaps

Every clinical evaluation has gaps.

The issue arises when those gaps are:

• Ignored
• Minimized
• Or assumed to be covered by literature

Under MDR, regulators expect transparency:

• Identify gaps
• Justify them
• Address them through PMS or PMCF

Literature alone rarely closes all gaps.

What Regulators Expect Instead

Under EU MDR, clinical evaluation must be:

• Device-specific
• Scientifically justified
• Based on multiple evidence sources

This includes:

• Clinical investigations (if required)
• Post-market data
• Literature
• Risk management outputs
• State-of-the-art analysis

Literature plays a role—but it is only one part of the overall framework.

When Can Literature Be Sufficient?

In some cases, literature-only approaches may work:

• Well-established, low-risk devices
• Technologies with extensive clinical history
• Strong equivalence with high comparability
• High-quality, directly relevant published data

Even in these scenarios, the justification must be strong and well-documented.

A Better Strategy for Using Literature

To avoid failure, manufacturers should adopt a more structured approach:

1. Use Literature as Supporting Evidence

Do not rely on it as the sole source.

2. Demonstrate Strong Comparability

Clearly explain how the literature applies to your device

3. Focus on Relevant Studies

Choose studies that directly align with your device and claims.

4. Perform Critical Appraisal

Evaluate the quality and limitations of each study.

5. Address Gaps Transparently

Acknowledge uncertainties and justify how they are managed.

6. Integrate Multiple Evidence Sources

Combine literature with:

• Post-market surveillance data
• Clinical experience
• Risk management

The Required Mindset Shift

The failure of literature-only approaches is not due to literature itself.

It is due to how it is used.

Old mindset: Literature can replace clinical evidence

New mindset: Literature supports clinical evidence—but must be justified and integrated

Final Thought

Literature remains a powerful tool in clinical evaluation.

But under EU MDR, it must be used strategically, not blindly.

Because in the end:

It’s not about how many studies you include
It’s about how well those studies support your device

And that is why literature-only clinical evidence often fails.